Metabolic HealthNew GLP-1/Glucagon Dual Agonist Mazdutide Cuts Body Weight Up to 18% in 32 Weeks
Mazdutide is a novel drug that activates both GLP-1 and glucagon receptors — a different mechanism than semaglutide or tirzepatide. In this US-based phase 2 trial of 179 adults with obesity or overweight (no type 2 diabetes), participants received weekly injections of mazdutide at 3–6 mg, 10 mg, or 16 mg, or placebo for 48 weeks. At 32 weeks, the 10 mg dose produced 15.6% average weight loss and the 16 mg dose produced 18.1%, compared to just 0.9% with placebo. Side effects were mostly mild-to-moderate gastrointestinal symptoms. The 16 mg group had the highest dropout rate at 20% due to GI issues. These results position mazdutide as a potentially competitive obesity therapy with a distinct receptor profile that may offer metabolic advantages beyond weight loss alone.
